Quote:

---

And if there is no deal...I have no idea how the company will raise the money to pay Syneos to sell leronlimab and whatever else it takes to get through commercialization. That would take up to 150 million shares at .30 and there is no way the company could sell anywhere near that, not by a long shot.

---

A soft roll out should be around $25 million. Whether we would pay that or Syneos would pay would depend on how the deal would have been structured. The Syneos deal would have been based on royalties to Syneos so no fixed cost to us. If Syneos was paying for launch costs they would of been paid higher royalties.